Artelo Biosciences, Inc. (ARTL) |
|
3.2 -0.01 (-0.31%)
|
01-27 15:59 |
|
Open: |
3.1595 |
Pre. Close: |
3.21 |
|
High:
|
3.22 |
Low:
|
3.14 |
|
Volume:
|
7,641 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:36 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.08 One year: 4.77 |
| Support: |
Support1: 3 Support2: 2.7 |
| Resistance: |
Resistance1: 3.5 Resistance2: 4.08 |
| Pivot: |
3.21  |
| Moving Average: |
MA(5): 3.14 MA(20): 3.13
MA(100): 3.09  MA(250): 4.45 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 45.5 %D(3): 41.6 |
| RSI: |
RSI(14): 55 |
| 52-week: |
High: 11.06 Low: 0.3 |
| Average Vol(K): |
3-Month: 23 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ARTL ] has closed above bottom band by 47.9%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.22 - 3.24 |
3.24 - 3.26 |
|
Low:
|
3.1 - 3.12 |
3.12 - 3.14 |
|
Close:
|
3.17 - 3.2 |
3.2 - 3.23 |
|
Company Description |
|
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. |
Headline News |
Fri, 27 Jan 2023
Director dealings: Spouse of Henry Boot CEO makes share purchase - ShareCast
Thu, 26 Jan 2023
2023-01-26 | NDAQ:ARTL | Press Release | Artelo Biosciences Inc. - Stockhouse
Wed, 25 Jan 2023
Gloria Artl Obituary (1942 - 2023) - Legacy.com
Wed, 18 Jan 2023
70% upside! Adani Enterprises shares can hit Rs 5,999 level in 24 months, says Ventura Securities - Business Today
Mon, 16 Jan 2023
Pro-life movement experiencing post-Roe paradigm shift - Arkansas Catholic
Tue, 16 Aug 2022
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
4.7 (%) |
|
Shares Short
|
127 (K) |
|
Shares Short P.Month
|
89 (K) |
Stock Financials |
|
EPS
|
-0.32 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-9 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-10.13 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.41 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.04 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-20 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
